Amorfix and Cangene collaborate on development of therapeutic antibodies for oncology

Amorfix and Cangene collaborate on development of therapeutic antibodies for 
oncology 
TSX: AMF 
TORONTO, Dec. 6, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
it has established a collaboration with CNJ Holdings Inc., a wholly-owned 
subsidiary of Cangene Corporation, for the identification and development of 
therapeutic antibodies against proprietary disease specific epitopes (DSEs) 
identified using Amorfix's ProMIS™ discovery technology for the treatment of 
various oncology indications. 
"This collaboration represents the ideal situation where two companies come 
together with complementary expertise, resources and technology in a united 
effort to identify and develop novel antibody therapeutics for the treatment 
of cancer", said Dr. Robert Gundel, Amorfix President and CEO. "Establishing 
partnerships and strategic alliances to accelerate the discovery, development 
and commercialization of therapeutic antibodies is part of our overall 
strategy to build our product pipeline." 
Amorfix's current therapeutic portfolio includes antibodies directed against a 
number of misfolded protein targets for the treatment of a variety of cancers 
including ovarian cancer, melanoma and leukemia. This new collaboration with 
Cangene allows Amorfix continue to build and expand its innovative product 
pipeline of cancer therapeutics. 
"We are excited about this collaboration with Amorfix which brings new energy 
to our R&D pipeline development efforts" said John Sedor, Cangene's President 
and CEO. "This is an opportunity to leverage our core competencies to 
accelerate the development of therapeutic antibodies to novel targets in the 
oncology space" he added. 
The terms of the collaboration were not disclosed. 
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
a cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD), and 
an ultrasensitive method for detecting the hallmark of AD, aggregated 
beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For 
more information about Amorfix, visit www.amorfix.com. 
About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of 
the nation's oldest and largest biopharmaceutical companies. It is focused on 
the development and commercialization of specialty therapeutics. Cangene's 
products are sold worldwide and include products that have been accepted into 
the U.S. Strategic National Stockpile. Cangene has offices in three locations 
across North America. It operates manufacturing facilities in Winnipeg, 
Manitoba and Baltimore, Maryland (through its wholly owned subsidiary, Cangene 
bioPharma, Inc.) where it produces its own products and undertakes contract 
manufacturing for a number of customers. Cangene also operates a 
plasma-collection facility in Winnipeg, Manitoba under the name Cangene Plasma 
Resources. Its U.S. sales and marketing office is located in Philadelphia, 
Pennsylvania. For more information about Cangene, visit the Company's 
website at www.cangene.com. 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. This information release may contain certain 
forward-looking information. Such information involves known and unknown 
risks, uncertainties and other factors that may cause actual results, 
performance or achievements to be materially different from those implied by 
statements herein, and therefore these statements should not be read as 
guarantees of future performance or results. All forward-looking statements 
are based on the Company's current beliefs as well as assumptions made by and 
information currently available to it as well as other factors. Readers are 
cautioned not to place undue reliance on these forward-looking statements, 
which speak only as of the date of this press release. Due to risks and 
uncertainties, including the risks and uncertainties identified by the Company 
in its public securities filings, actual events may differ materially from 
current expectations. The Company disclaims any intention or obligation to 
update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com  
Janet Clennett Acting Chief Financial Officer Amorfix Life Sciences Ltd. Tel: 
(416) 847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com   
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/December2012/06/c6826.html 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC HEA  
-0- Dec/06/2012 13:37 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.